Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureYu-ting Gan, Qing-chun Diao, Bing-jun Shi, Xun Zhou, Feng-lin Chen
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
10.1016/s0140-6736(20)30732-7 · 2020
Long-Term safety of abrocitinib in moderate-to-severe atopic dermatitis: integrated analysis by Age
10.1016/j.jaip.2025.02.040 · 2025
Abrocitinib for atopic dermatitis: a step forward
10.1016/s0140-6736(20)31284-8 · 2020
Efficacy and safety of abrocitinib in elderly Chinese patients with moderate-to-severe atopic dermatitis: a single-center, retrospective study
2026
Abrocitinib safety in geriatric patients: the need for a holistic assessment
10.1016/j.jaad.2026.02.126 · 2026
No additional external references are available.